Key Takeaways on Optimizing Multiple Myeloma Care

Opinion
Video

Caitlin Costello, MD, offers concluding remarks and guidance to healthcare providers on optimizing multiple myeloma patient care.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
      Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
      Frontline Setting of Pancreatic Cancer
      Frontline Setting of Pancreatic Cancer
      Treatment Algorithm for Metastatic Pancreatic Cancer
      Treatment Algorithm for Metastatic Pancreatic Cancer
      Role of Radiation in Pancreatic Cancer Treatment
      Role of Radiation in Pancreatic Cancer Treatment
      NGS and Germline Testing in Pancreatic Cancer
      NGS and Germline Testing in Pancreatic Cancer
      Overview of Pancreatic Cancer Treatment Approach
      Overview of Pancreatic Cancer Treatment Approach
      Deciding Which RP to Utilize
      Deciding Which RP to Utilize
      Making Sense of PARP Inhibitors
      Making Sense of PARP Inhibitors
      Consideration for Other Androgen Receptor Inhibitors
      Consideration for Other Androgen Receptor Inhibitors
      Prostate Cancer in 2025
      Prostate Cancer in 2025
      Related Content
      Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.

      Data Show Enduring Responses With Talquetamab Combo in R/R Multiple Myeloma

      Gina Mauro
      June 18th 2025
      Article

      Findings from the phase 1b TRIMM-3 trial support the potential activity of PD-1 inhibition in patients with relapsed/refractory multiple myeloma.

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

      Samantha Shenoy, NP, MSN
      October 14th 2024
      Podcast

      Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

      Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

      Subcutaneous Isatuximab Shows Noninferior Efficacy in Multiple Myeloma

      Kristi Rosa
      June 16th 2025
      Article

      Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

      James R. Berenson, MD, FACP
      September 30th 2024
      Podcast

      James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

      Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

      Quarterly MRD Monitoring After Daratumumab Allows Relapse Detection in Multiple Myeloma

      Ariana Pelosci
      June 14th 2025
      Article

      Results of the PREDATOR-MRD trial found that daratumumab could help predict MRD response for patients with multiple myeloma.

      The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.

      Cilta-Cel Demonstrates "Curative Potential" in R/R Multiple Myeloma

      Gina Mauro
      June 9th 2025
      Article

      The median overall survival with cilta-cel exceeds 5 years among patients with relapsed/refractory multiple myeloma in the CARTITUDE-1 trial.